<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026256</url>
  </required_header>
  <id_info>
    <org_study_id>2018P002537</org_study_id>
    <nct_id>NCT04026256</nct_id>
  </id_info>
  <brief_title>Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration</brief_title>
  <official_title>Mechanisms Underlying the Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine, via iliac crest bone biopsies, the mechanism of
      combined teriparatide and denosumab on the bone of postmenopausal osteoporotic women after 3
      months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 3 Months in Cancellous Bone Formation Rate</measure>
    <time_frame>3 months after first dose of study drug</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Teriparatide only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily subcutaneous injection teriparatide for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one dose of subcutaneous injection denosumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab and teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily subcutaneous injection teriparatide for 3 months plus one dose of subcutaneous injection denosumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>teriparatide daily subcutaneous injection</description>
    <arm_group_label>Denosumab and teriparatide</arm_group_label>
    <arm_group_label>Teriparatide only</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>denosumab subcutaneous injection</description>
    <arm_group_label>Denosumab and teriparatide</arm_group_label>
    <arm_group_label>Denosumab only</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women aged 45+

          -  postmenopausal

          -  osteoporotic with high risk of fracture

        Exclusion Criteria:

          -  significant previous use of bone health modifying treatments

          -  known congenital or acquired bone disease other than osteoporosis

          -  significant renal disease, liver disease, cardiopulmonary disease, or psychiatric
             disease

          -  abnormal calcium or parathyroid hormone level

          -  serum vitamin D &lt;20 ng/mL or &gt;60ng/mL

          -  serum alkaline phosphatase above upper normal limit with no explanation

          -  anemia (hematocrit &lt;32%)

          -  history of malignancy (except non-melanoma skin carcinoma), radiation therapy, or
             gouty arthritis

          -  history of urolithiasis within the last one year

          -  excessive alcohol use or substance abuse

          -  use of oral or parenteral glucocorticoids for more than 14 days within the past 6
             months

          -  extensive dental work involving extraction or dental implant within the past or
             upcoming 2 months

          -  known sensitivity to mammalian cell-derived drug products

          -  known contraindications to denosumab, teriparatide, or any of their excipients

          -  known contraindications to tetracycline, demeclocycline, or other antibiotics in this
             drug class

          -  continuous use of tetracycline for &gt;1-month duration within the last 10 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Leder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabashini Ramchand, MD</last_name>
    <phone>617-643-6891</phone>
    <email>sramchand@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalie David, BS</last_name>
    <phone>617-726-6129</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabashini Ramchand</last_name>
      <phone>617-643-6891</phone>
      <email>sramchand@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natalie David</last_name>
      <phone>617-726-6129</phone>
      <email>ndavid2@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Benjamin Leder, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>histomorphometry</keyword>
  <keyword>bone density</keyword>
  <keyword>teriparatide</keyword>
  <keyword>denosumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

